Literature DB >> 7606956

Mitochondrial disease. Pulmonary function, exercise performance, and blood lactate levels.

R J Dandurand1, P M Matthews, D L Arnold, D H Eidelman.   

Abstract

Mitochondrial diseases are a heterogeneous group of disorders in which it has been suggested that genetic defects in oxidative phosphorylation lead to specific alterations in exercise performance and lactate metabolism during exercise. To investigate this possibility, we evaluated pulmonary function tests, incremental exercise testing, and serial blood lactate levels in a group of subjects with mitochondrial disease (M) and compared them with a group of patients with nonmitochondrial (N) myopathies and healthy subjects (H). The two groups were demographically comparable and had no significant differences in pulmonary function. Both groups showed similar degrees of reduced exercise tolerance compared with a group of healthy subjects (M: 61.08% predicted VO2max +/- 19.58 SD, n = 13; N: 62.14 +/- 28.89, n = 7; H: 115.17 +/- 19.35, n = 12; p < 0.001). The mitochondrial disease group more frequently showed abnormalities in cardiac response to exercise than did the nonmitochondrial myopathy subjects (M: 12/13, N: 3/7, H: 3/12, p = 0.002). Minute ventilation greater than predicted occurred with similar frequency in both groups. Although resting lactate level was increased in some subjects with mitochondrial myopathy compared with disease controls, there were no differences between groups for peak venous lactate level normalized for oxygen uptake or the rate of lactate clearance. These findings, while confirming the presence of some specific abnormalities in mitochondrial disease, are against the notion that exercise limitation in this condition directly results from specific abnormalities in oxidative metabolism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606956     DOI: 10.1378/chest.108.1.182

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Exertional dyspnea in mitochondrial myopathy: clinical features and physiological mechanisms.

Authors:  Katja Heinicke; Tanja Taivassalo; Phil Wyrick; Helen Wood; Tony G Babb; Ronald G Haller
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-08-03       Impact factor: 3.619

Review 2.  Metabolic myopathies: functional evaluation by different exercise testing approaches.

Authors:  L Volpi; G Ricci; D Orsucci; R Alessi; F Bertolucci; S Piazza; C Simoncini; M Mancuso; G Siciliano
Journal:  Musculoskelet Surg       Date:  2011-03-04

3.  Lactate increase and oxygen desaturation in mitochondrial disorders--evaluation of two diagnostic screening protocols.

Authors:  Frank Hanisch; Tobias Müller; Anett Muser; Marcus Deschauer; Stephan Zierz
Journal:  J Neurol       Date:  2006-04-20       Impact factor: 4.849

Review 4.  Diagnosis and treatment of mitochondrial myopathies.

Authors:  Gerald Pfeffer; Patrick F Chinnery
Journal:  Ann Med       Date:  2011-08-25       Impact factor: 4.709

5.  Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study.

Authors:  Fabrice Rannou; Arnaud Uguen; Virginie Scotet; Cédric Le Maréchal; Odile Rigal; Pascale Marcorelles; Eric Gobin; Jean-Luc Carré; Fabien Zagnoli; Marie-Agnès Giroux-Metges
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  Altered skeletal muscle (mitochondrial) properties in patients with mitochondrial DNA single deletion myopathy.

Authors:  Saskia Maria Gehrig; Violeta Mihaylova; Sebastian Frese; Sandro Manuel Mueller; Maria Ligon-Auer; Christina M Spengler; Jens A Petersen; Carsten Lundby; Hans H Jung
Journal:  Orphanet J Rare Dis       Date:  2016-07-29       Impact factor: 4.123

7.  Relationship between cardiopulmonary responses and isokinetic moments: the optimal angular velocity for muscular endurance.

Authors:  Chan-Bok Lee; Denny Eun; Kang-Ho Kim; Jae-Wan Park; Yong-Seok Jee
Journal:  J Exerc Rehabil       Date:  2017-04-30

8.  Exercise efficiency impairment in metabolic myopathies.

Authors:  Jean-Baptiste Noury; Fabien Zagnoli; François Petit; Pascale Marcorelles; Fabrice Rannou
Journal:  Sci Rep       Date:  2020-05-29       Impact factor: 4.379

9.  A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.

Authors:  Vincenzo Libri; Andrew P Brown; Giulio Gambarota; Jonathan Haddad; Gregory S Shields; Helen Dawes; David J Pinato; Ethan Hoffman; Peter J Elliot; George P Vlasuk; Eric Jacobson; Martin R Wilkins; Paul M Matthews
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.